PapersPMID:19584739
The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia.
melatoninWhat moved
1 findingHow to read these marks →- Decreases sleep onset latency
very limitedreplicated ×11
“By the end of the double-blind treatment, the PRM group had significantly shorter sleep onset latency (9 min; P = 0.02) compared with the placebo group and scored significantly better in the Critical Flicker Fusion Test (P = 0.008) without negatively affecting sleep structure and architecture.”
- Study
- RCT
- Duration
- 3 weeks
- Dose studied
- prolonged-release melatonin 2 mg nightly
- Population
- Adults aged 55 years and older with primary insomnia (DSM-IV)
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- Adults aged 55 years and older with primary insomnia (DSM-IV)
- Participants
- 40
- Comparator
- placebo
- Duration
- 21 days
- Endpoints measured
- 4